{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:30:36Z","timestamp":1793255436815,"version":"4.5.0"},"reference-count":33,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100015769","name":"Dexcom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Maturity-onset diabetes of the young (MODY) caused by pathogenic variants in HNF1A is a common form of monogenic diabetes. Sulfonylurea drugs are considered first-line treatment of HNF1A-MODY (MODY3), but intensified treatment is often needed. HNF1A encodes a transcription factor involved in the regulation of the sodium\u2013glucose cotransporter 2 (SGLT2). Accordingly, the glucose-lowering efficacy of SGLT2 inhibitors in HNF1A-MODY is questionable. Here, we assess the glucose-lowering effect of the SGLT2 inhibitor empagliflozin as an add-on for treatment of individuals with HNF1A-MODY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>MOD3ST-TRIAL was a randomized, double-blind, placebo-controlled crossover trial. Adults with HNF1A-MODY treated with at least one glucose-lowering drug were randomized to be treated with empagliflozin 25 mg for 4 weeks followed by a 2-week washout period and then received placebo for 4 weeks or the opposite sequence. The primary outcome was mean glucose concentration assessed by 10 days of continuous glucose monitoring (CGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Nineteen individuals were randomized and 18 participants (n = 10 women [56%]; median [Q1, Q3] HbA1c 7.5% [7.0, 8.4] or 58 [53, 68] mmol\/mol, mean [SD] CGM glucose concentration 10.4 [2.5] mmol\/L) completed the study. Compared with placebo, empagliflozin lowered the mean glucose level 2.3 mmol\/L (95% CI 1.3 to 3.3; P = 0.0001). There were no significant differences in hypoglycemic outcomes. Adverse events were generally mild and transient, and no severe adverse events or study drug discontinuations were attributable to empagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Empagliflozin used for 4 weeks in adjunction with other glucose-lowering treatments markedly improved glycemia compared with placebo in individuals with HNF1A-MODY without significantly increasing risk of hypoglycemia or unexpected adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2572","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T17:02:24Z","timestamp":1768237344000},"page":"1166-1174","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":4,"title":["Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-9898","authenticated-orcid":false,"given":"Henrik","family":"Maagensen","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine O.","family":"H\u00f8yerup","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne S.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.B.","family":"Thuesen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen 2 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Forman","sequence":"additional","affiliation":[{"name":"Section of Biostatistics, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen 3 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Medical Diagnostic Center, University Clinic for Innovative Patient Pathways, Regional Hospital Central Jutland 4 , Viborg, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University 5 , Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[{"name":"Center for Clinical Metabolic Research, Copenhagen University Hospital \u2013 Herlev and Gentofte 6 , Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 7 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen 2 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"H\u00e6dersdal","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"St\u00f8y","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University 5 , Aarhus, Denmark"},{"name":"Steno Diabetes Center Aarhus, Aarhus University Hospital 8 , Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-6787","authenticated-orcid":false,"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 7 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026062214530183000_B1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/diab.24.1.44","article-title":"A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people","volume":"24","author":"Tattersall","year":"1975","journal-title":"Diabetes"},{"key":"2026062214530183000_B2","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1002\/edm2.372","article-title":"Statistical evidence for high-penetrance MODY-causing genes in a large population-based cohort","volume":"5","author":"Billings","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026062214530183000_B3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/pedi.13426","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents","volume":"23","author":"Greeley","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026062214530183000_B4","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/diabetes.50.2007.S101","article-title":"\u03b2-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1\u03b1 and glucokinase mutations","volume":"50","author":"Pearson","year":"2001","journal-title":"Diabetes"},{"key":"2026062214530183000_B5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1007\/s001250051558","article-title":"Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state","volume":"43","author":"Tripathy","year":"2000","journal-title":"Diabetologia"},{"key":"2026062214530183000_B6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/diacare.19.9.915","article-title":"Diabetes complications in NIDDM kindreds linked to the MODY3 locus cn Chromosome 12q","volume":"19","author":"Velho","year":"1996","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001250050931","article-title":"Chronic diabetic complications in patients with MODY3 diabetes","volume":"41","author":"Isomaa","year":"1998","journal-title":"Diabetologia"},{"key":"2026062214530183000_B8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"key":"2026062214530183000_B9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diacare.29.02.06.dc05-1314","article-title":"Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3","volume":"29","author":"Tuomi","year":"2006","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2337\/dc13-3007","article-title":"Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial","volume":"37","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B11","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00125-018-4728-6","article-title":"A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin","volume":"61","author":"Shepherd","year":"2018","journal-title":"Diabetologia"},{"key":"2026062214530183000_B12","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc20-0408","article-title":"Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA)","volume":"43","author":"Christensen","year":"2020","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026062214530183000_B14","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2337\/db17-0100","article-title":"Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes","volume":"66","author":"Al-Jobori","year":"2017","journal-title":"Diabetes"},{"key":"2026062214530183000_B15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062214530183000_B16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026062214530183000_B17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/embo-reports\/kvd071","article-title":"HNF1alpha controls renal glucose reabsorption in mouse and man","volume":"1","author":"Pontoglio","year":"2000","journal-title":"EMBO Rep"},{"key":"2026062214530183000_B18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.118.111807","article-title":"Nucleosome positioning and gene regulation of the SGLT2 gene in the renal proximal tubular epithelial cells","volume":"94","author":"Takesue","year":"2018","journal-title":"Mol Pharmacol"},{"key":"2026062214530183000_B19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/(SICI)1096-9136(199810)15:10<816::AID-DIA714>3.0.CO;2-P","article-title":"A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1) gene","volume":"15","author":"Menzel","year":"1998","journal-title":"Diabet Med"},{"key":"2026062214530183000_B20","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/dc25-0737","article-title":"Effect of SGLT2 inhibition on glucosuria during a hyperglycemic clamp in HNF1A-MODY (MODY3) and type 2 diabetes","volume":"48","author":"Maagensen","year":"2025","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B21","doi-asserted-by":"crossref","first-page":"e15387","DOI":"10.1111\/dme.15387","article-title":"Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)","volume":"41","author":"Maagensen","year":"2024","journal-title":"Diabet Med"},{"key":"2026062214530183000_B22","first-page":"21","article-title":"The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3","volume":"2021","author":"Sriravindrarajah","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026062214530183000_B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062214530183000_B24","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026062214530183000_B25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/dia.2017.0455","article-title":"Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control","volume":"20","author":"Riddlesworth","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"2026062214530183000_B26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/clinchem\/hvac192","article-title":"Within-person and between-sensor variability in continuous glucose monitoring metrics","volume":"69","author":"Selvin","year":"2023","journal-title":"Clin Chem"},{"key":"2026062214530183000_B27","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2337\/db20-0074","article-title":"GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1\u03b1 mutation carriers","volume":"69","author":"Christensen","year":"2020","journal-title":"Diabetes"},{"key":"2026062214530183000_B28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2174\/1573399812666160613113556","article-title":"Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials","volume":"13","author":"Levine","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"2026062214530183000_B29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1464-5491.2009.02913.x","article-title":"Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene","volume":"27","author":"Steele","year":"2010","journal-title":"Diabet Med"},{"key":"2026062214530183000_B30","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Kinduryte Schorling","year":"2020","journal-title":"Adv Ther"},{"key":"2026062214530183000_B31","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2026062214530183000_B32","author":"Jardiance - Summary of Product Characteristics (SmPC). European Medicines Agency, 2025"},{"key":"2026062214530183000_B33","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.diabet.2021.101248","article-title":"Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3","volume":"47","author":"Phan","year":"2021","journal-title":"Diabetes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/7\/1166\/853635\/dc252572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/7\/1166\/853635\/dc252572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:53:13Z","timestamp":1782154393000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/7\/1166\/164242\/Empagliflozin-in-HNF1A-MODY-MODY3-A-Randomized"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2572","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}